Cypherpunk Technologies (NASDAQ:CYPH) Issues Earnings Results

Cypherpunk Technologies (NASDAQ:CYPH) issued its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.42), FiscalAI reports.

Cypherpunk Technologies Price Performance

Cypherpunk Technologies stock opened at $1.04 on Tuesday. The stock’s 50-day moving average is $0.84 and its 200-day moving average is $1.00. The company has a market cap of $110.72 million, a price-to-earnings ratio of -51.97 and a beta of -0.09. Cypherpunk Technologies has a 12 month low of $0.23 and a 12 month high of $3.70.

Hedge Funds Weigh In On Cypherpunk Technologies

A number of large investors have recently modified their holdings of CYPH. Acadian Asset Management LLC raised its holdings in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after buying an additional 1,056,047 shares during the period. HighTower Advisors LLC purchased a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $59,000. Geode Capital Management LLC purchased a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $615,000. LPL Financial LLC purchased a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $38,000. Finally, State Street Corp purchased a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $163,000. 30.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CYPH has been the topic of a number of research analyst reports. Wall Street Zen lowered Cypherpunk Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings raised Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.